A G4 polyamidoamine (PAMAM) as carrier, an RNA aptamer that specifically recognizes PSMA was used as a prostate cancer targeting moiety, Doxorubicin (Dox) was chosen as chemotherapeutic agent, and the unmethylated CpG duplex oligonucleotides (dONT) as an immuno-stimulant. This evidence concerns the gene FOLH1 and prostate cancer.